Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534164 | 0.98 | THRB (0.34) | THRBTSHRALDH1A1MAPTCNR1 | |
| Chloromethane SCHEMBL5914760 | 0.96 | THRB (0.33) | THRBTSHRALDH1A1MAPTCNR1 | |
| Hydrochloric Acid SCHEMBL8440810 | 0.88 | ALDH1A1 (0.47) | THRBTSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL8442139 | 0.87 | TET2 (0.32) | THRB | |
| SCHEMBL9297852 | 0.86 | TSHR (0.39) | THRBTSHR | |
| SCHEMBL1783415 | 0.86 | ALDH1A1 (0.48) | THRBTSHRALDH1A1 | |
| SCHEMBL2031674 | 0.86 | — | — | |
| SCHEMBL5057227 | 0.84 | THRB (0.33) | THRBTSHR | |
| SCHEMBL28791986 | 0.81 | TSHR (0.44) | THRBTSHRALDH1A1 | |
| SCHEMBL29117402 | 0.81 | TSHR (0.30) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023137224-A2 | BIODEGRADABLE MICROCAPSULES WITH IMPROVED STORAGE STABILITY, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF | ISP INVESTMENTS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| US-10918597-B2 | Gastroretentive dosage forms for sustained drug delivery | KASHIV SPECIALTY PHARMACEUTICALS, LLC (US) | 2021-02-16 | — | — | US | claimed |
| US-20200337998-A1 | GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERY | KASHIV PHARMA LLC (US) | 2020-10-29 | — | — | US | claimed |
| WO-2008059522-A2 | HERBAL GASTROINTENSTINAL CONTROLLED DRUG DELIVERY DOSAGE FORMS INCLUDING PELLETS AND PROCESS FOR THEIR PREPARATION | UNIJULES LIFE SCIENCES LTD (IN) | 2008-05-22 | — | — | WO | claimed |
| US-5932249-A | FIRST LACQUER COATING OF AT LEAST ONE LACQUER INSOLUBLE IN GASTRIC FLUIDS BUT SOLUBLE IN INTESTINAL FLUIDS AND ONE LACQUER INSOLUBLE IN BOTH GASTRIC AND INTESTINAL FLUIDS; AND D) A SECOND LACQUER COATING CONSISTING OF AT LEAST ONE LACQUER | DR. FALK PHARMA GMBH (DE) | 1999-08-03 | — | — | US | claimed |
| EP-4360705-A2 | SUSTAINED RELEASE COMPOSITIONS COMPRISING LIOTHYRONINE | Amneal Complex Products Research LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11964048-B2 | Sustained release compositions comprising liothyronine | AMNEAL COMPLEX PRODUCTS RESEARCH LLC | 2024-04-23 | — | — | US | disclosed |
| EP-4090313-B1 | SUSTAINED RELEASE COMPOSITIONS COMPRISING LIOTHYRONINE | AMNEAL COMPLEX PRODUCTS RES LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240034657-A1 | TREATMENT OF AQUEOUS SYSTEMS | MFG CHEMICAL, LLC (US) | 2024-02-01 | — | — | US | disclosed |
| US-20230330006-A1 | Sustained Release Compositions Comprising Liothyronine | Amneal Complex Products Rearch LLC (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2023137224-A2 | BIODEGRADABLE MICROCAPSULES WITH IMPROVED STORAGE STABILITY, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF | ISP INVESTMENTS LLC (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023031887-A1 | FORMULATIONS OF CONTROLLED RELEASE PENETRATING MEMBERS FOR DRUG DELIVERY IN THE SMALL INTESTINE WALL | ALMA THERAPEUTICS LTD (IL) | 2023-03-09 | — | — | WO | disclosed |
| WO-2010046375-A1 | UREA-BASED FILM-FORMING SOLUTION FOR TREATING NAIL PSORIASIS | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2010-04-29 | — | — | WO | disclosed |
| US-20090263481-A1 | LEVETIRACETAM FORMULATIONS | DR. REDDY'S LABORATORIES, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009007388-A1 | STABLE PHARMACEUTICAL COMPOSITION COMPRISING A HYDROSOLUBLE VINFLUNINE SALT | PIERRE FABRE MEDICAMENT (FR) | 2009-01-15 | — | — | WO | disclosed |
| US-20060150344-A1 | Method for smoothing fibers containing keratin | HENKEL AG & CO. KGAA (DE) | 2006-07-13 | — | — | US | disclosed |
| CN-1193730-C | Application of glyceryl triacetate in treatment of onychomycosis | HOECHST AG (DE) | 2005-03-23 | — | — | CN | disclosed |
| CN-1113670-C | Improving the stability of prostaglandin drugs | BIOLOG TECH DEV CT (CN) | 2003-07-09 | — | — | CN | disclosed |
| CN-1211450-A | Improving the stability of prostaglandin drugs | BIOLOG TECH DEV CENTER (CN) | 1999-03-24 | — | — | CN | disclosed |
| CN-1156958-A | Use of glyceryl triacetate for treating onychomycoses | HOECHST AG (DE) | 1997-08-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060150344-A1 | Method for smoothing fibers containing keratin | KRT18, KIF5B, KIF5A | THRB 4779/4885TSHR 4457/4885ALDH1A1 3827/4885 |
| US-20090263481-A1 | LEVETIRACETAM FORMULATIONS | EPM2A, SLC6A1, SLC6A13 | THRB 4294/4885TSHR 2615/4885ALDH1A1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.